Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $195,872 | $190,870 | $192,462 | $249,814 |
| - Cash | $7,616 | $6,896 | $9,882 | $9,799 |
| + Debt | $15,275 | $15,873 | $17,946 | $19,251 |
| Enterprise Value | $203,531 | $199,847 | $200,526 | $259,266 |
| Revenue | $41,950 | $40,109 | $43,653 | $43,075 |
| % Growth | 4.6% | -8.1% | 1.3% | – |
| Gross Profit | $21,325 | $20,037 | $22,323 | $23,214 |
| % Margin | 50.8% | 50% | 51.1% | 53.9% |
| EBITDA | $10,834 | $10,605 | $11,888 | $12,159 |
| % Margin | 25.8% | 26.4% | 27.2% | 28.2% |
| Net Income | $13,402 | $5,723 | $6,933 | $7,071 |
| % Margin | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS Diluted | 7.64 | 3.27 | 3.91 | 3.94 |
| % Growth | 133.6% | -16.4% | -0.8% | – |
| Operating Cash Flow | $8,558 | $7,261 | $9,581 | $10,533 |
| Capital Expenditures | -$2,207 | -$2,202 | -$1,777 | -$1,885 |
| Free Cash Flow | $6,351 | $5,059 | $7,804 | $8,648 |